SRPT — Sarepta Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 873303 ·
Last close
$18.80
Market Cap
$1.99B
52W High
$25.32
52W Low
$14.68
ADV30
3,032,640
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 401,251,000 | 251,866,000 | 52,291,000 | -4,890,000 | 3,188,512,000 | 571,148,000 | 1,660,714,000 |
| Mar 2026 | 730,803,000 | 622,035,000 | 358,433,000 | 330,959,000 | 3,178,934,000 | 464,450,000 | 1,673,832,000 |
| Dec 2025 | 442,934,000 | 44,226,000 | -410,084,000 | -282,847,000 | 3,349,703,000 | 801,282,000 | 2,209,081,000 |
| Sep 2025 | 399,356,000 | 248,581,000 | -62,879,000 | -179,947,000 | 3,493,437,000 | 613,077,000 | 2,173,317,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$175,275,000
Investing CF
$226,428,000
Financing CF
$-180,574,000
CapEx
$-67,040,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.96
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,550,915,000
Inventory
$904,273,000
Receivables
$438,814,000
ST Investments
$217,341,000
EBIT TTM
$-59,290,000
Pretax Income TTM
$-130,920,000
Interest Exp TTM
$71,630,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,974,343,936
EBITDA
$-17,533,000
Free Cash Flow
$22,139,876
Enterprise Value
$2,433,994,496
Total Cash
$788,489,024
Total Debt
$1,062,411,008
Shares Out
105,627,021
Trailing EPS
$-1.57
Book Value
$14.46
ROE
-9.5%
ROA
-1.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,198,237,000 | -657,772,000 | -713,410,000 | 3,349,703,000 | 2,209,081,000 | 1,140,622,000 | -205,479,000 |
| Dec 2024 | 1,901,979,000 | 218,081,000 | 235,239,000 | 3,963,173,000 | 2,435,431,000 | 1,527,742,000 | -205,787,000 |
| Dec 2023 | 1,243,336,000 | -267,824,000 | -535,977,000 | 3,264,576,000 | 2,405,239,000 | 859,337,000 | -500,993,000 |
| Dec 2022 | 933,013,000 | -536,201,000 | -703,488,000 | 3,128,366,000 | 2,743,416,000 | 384,950,000 | -325,346,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.57
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.50 · spot: $18.80 · call volume: 550 · put volume: 354
Expected Move to 2027-02-19:
±$7.04
(37.45%) —
implied range
$11.76 –
$25.84
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGIO | AGIOS PHARMACEUTICALS, INC. | $2.00B | $33.42 | — |
| URGN | UroGen Pharma Ltd. | $2.00B | $40.90 | — |
| BHVN | Biohaven Ltd. | $2.00B | $13.27 | — |
| NUVB | Nuvation Bio Inc. | $1.96B | $5.60 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.01B | $139.83 | — |
News headlines (Yahoo Finance, 1h cache)
Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn
2026-09-26 20:07 · Yahoo
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
2026-09-25 12:30 · Yahoo
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
2026-09-15 09:58 · Yahoo
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
2026-09-15 05:02 · Yahoo
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
2026-09-08 13:00 · Yahoo
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
2026-09-04 15:30 · Yahoo
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-31 20:30 · Yahoo
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
2026-08-27 19:00 · Yahoo
Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value
2026-08-25 10:11 · Yahoo
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
2026-09-08 15:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.